A major new ruling from the Fifth Circuit Court of Appeals could have significant implications for how the FDA enforces the Tobacco Control Act (TCA) against vapor and nicotine companies moving forward. 

While the decision does not weaken the FDA’s authority to regulate vapor products, it may dramatically impact the agency’s ability to pursue enforcement actions through its current administrative process. 

The ruling is already being viewed as one of the most important tobacco-related administrative law decisions in recent years. 

 

The Court Reaffirmed FDA Authority Over Vapor Products 

 

First, it is important to clarify what this ruling does not do. 

The Fifth Circuit did not strike down the Tobacco Control Act. 

The court did not invalidate the Deeming Rule. 

The ruling does not remove PMTA requirements or legalize unauthorized products. 

In fact, the court strongly reaffirmed that Congress gave the FDA authority to regulate tobacco and nicotine products under the TCA, including products deemed under FDA’s authority through the 2016 Deeming Rule. 

This portion of the ruling strengthens FDA’s overall regulatory authority and weakens future arguments claiming the agency lacks jurisdiction over modern nicotine products. 

 

Where the FDA Lost Ground 

 

The most significant part of the decision focused on enforcement procedures. 

The Fifth Circuit ruled that the FDA’s use of administrative proceedings to pursue punitive monetary penalties violated the Seventh Amendment right to a jury trial. 

The decision builds on the U.S. Supreme Court’s recent ruling in SEC v. Jarkesy, which limited federal agencies’ ability to impose penalties through internal administrative courts instead of federal judicial proceedings. 

For the tobacco industry, this could have major implications. 

Historically, the FDA has relied heavily on administrative enforcement mechanisms, including: 

• civil monetary penalties, 
• administrative hearings, 
• warning letter escalation, 
• and internally adjudicated enforcement actions. 

 

The court’s ruling signals that certain enforcement actions may now require full federal court proceedings instead of remaining within the FDA’s administrative structure. 

 

What This Could Mean for the Vapor Industry 

 

While the decision does not eliminate FDA enforcement authority, it could substantially slow or complicate enforcement efforts. 

If more cases must move through federal court systems: 

• enforcement actions may take longer, 
• litigation costs could increase, 
• and FDA may become more selective about which cases it pursues. 

 

This may particularly affect smaller retailers and distributors that previously faced rapid administrative escalation. 

The agency still retains significant enforcement tools, including: 

• warning letters, 
• import alerts, 
• product seizures, 
• injunctions, 
• PMTA denials, 
• and marketing denial orders. 

 

However, the process surrounding monetary penalties and administrative adjudication could face growing constitutional scrutiny. 

 

A Broader Shift in Administrative Law 

 

This case is part of a larger national trend where courts are increasingly examining the constitutional limits of federal agency power. 

Recent decisions involving multiple agencies have signaled that while Congress may authorize agencies to regulate industries, agencies must still operate within constitutional safeguards and procedural limits. 

For the vapor industry, this growing judicial scrutiny comes at a critical time as companies continue navigating: 

• PMTA uncertainty, 
• shifting enforcement priorities, 
• synthetic nicotine regulation, 
• flavor restrictions, 
• and increasing state-level registry laws. 

 

Why This Matters 

 

For years, many companies in the independent vapor industry have argued that FDA enforcement standards lacked consistency, transparency, and predictability. 

This ruling does not resolve those broader concerns overnight. 

But it does signal that courts are increasingly willing to examine how federal agencies exercise enforcement power — not just whether they possess that power. 

As litigation surrounding vapor regulation continues evolving, this Fifth Circuit decision could become an important precedent shaping the future relationship between the FDA, the courts, and the nicotine industry.